Wong E K, Eaves C, Klingemann H G
Terry Fox Laboratory, Vancouver, BC, Canada.
Bone Marrow Transplant. 1996 Jul;18(1):63-71.
Previous studies have suggested that autologous bone marrow or mobilized peripheral blood progenitor cell transplants activated by prior culture of the cells in IL-2 may capture some of the beneficial graft-versus-leukemia effects obtained with unmanipulated allogeneic, but not autologous, transplants. To investigate ways of improving this approach,we have compared the ability of two other immunomodulating cytokines, IL-7 and IL-12, either alone or in combination with IL-2, to stimulate human bone marrow cells (BMC) or peripheral blood cells (PBC) to acquire the potential to lyse K562 or Daudi cells. For these studies, we measured the cytotoxic activity of BMC or PBC both before and at the end of their incubation with various cytokine(s) using a standard 51-chromium release assay. Results suggest that IL-2 at optimal concentration induces cytotoxicity significantly higher than IL-7 or IL-12 when tested alone. At optimal concentration, the combination of IL-2 and IL-12 showed a synergistic effect for BMC. Such a synergistic effect could be observed for PBC only when suboptimal concentrations of IL-2 were used. In addition, the ability of the hematopoietic cells to reduce the number of K562 cells remaining at the end of various culture periods in the presence of the cytokines was measured. This was made possible by the use of a G418-resistant K562 cell line which could, in contrast to normal human BMC or PBC, form colonies that wer detectable after 1 week in methylcellulose cultures containing the neomycin analog G418. Normal human PBC, stimulated by either IL-7 or IL-12 alone effectively suppressed K562 proliferation in both of these assays, whereas no activity could be detected when BMC were incubated under the same conditions. On the other hand, cells from both sources displayed anti-leukemic activity when incubated with IL-2 and IL-12 together, although IL-2/IL-12-activated PBC suppressed the growth of co-cultivated K562-neor cells about eight-fold more efficiently than IL-2/IL-12-activated BMC. Cryopreservation and subsequent stimulation of BMC and PBC with cytokines did not cause a significant decrease in cytotoxicity or their ability to inhibit the growth of co-cultivated K562 cells compared to fresh cells. However, the synergistic effect observed with the combination of IL-2/IL-12 was no longer detectable for BMC. These results suggest that (1) PBC are superior to BMC with respect to developing effective natural killer (NK) activity after culture in cytokines and that, (2) the combination of IL-2 and IL-12 may be more effective than IL-2 alone to inhibit proliferation/growth of K562 cells.
先前的研究表明,通过白细胞介素-2(IL-2)对细胞进行预先培养激活的自体骨髓或动员的外周血祖细胞移植,可能会获得一些未处理的同种异体移植(而非自体移植)所产生的有益的移植物抗白血病效应。为了探索改进这种方法的途径,我们比较了另外两种免疫调节细胞因子IL-7和IL-12单独或与IL-2联合使用时,刺激人骨髓细胞(BMC)或外周血细胞(PBC)获得裂解K562或Daudi细胞能力的情况。在这些研究中,我们使用标准的51铬释放试验,在BMC或PBC与各种细胞因子孵育之前和结束时测量其细胞毒性活性。结果表明,单独测试时,最佳浓度的IL-2诱导的细胞毒性显著高于IL-7或IL-12。在最佳浓度下,IL-2和IL-12的组合对BMC显示出协同效应。仅当使用次优浓度的IL-2时,PBC才会出现这种协同效应。此外,还测量了造血细胞在细胞因子存在下减少不同培养期结束时剩余K562细胞数量的能力。这是通过使用一种对新霉素G418耐药的K562细胞系实现的,与正常人BMC或PBC不同,该细胞系在含有新霉素类似物G418的甲基纤维素培养基中培养1周后能够形成可检测的集落。单独用IL-7或IL-12刺激的正常人PBC在这两种试验中均有效抑制K562细胞增殖,而在相同条件下孵育BMC时未检测到活性。另一方面,当与IL-2和IL-12一起孵育时,两种来源的细胞均显示出抗白血病活性,尽管IL-2/IL-12激活的PBC抑制共培养的K562-neor细胞生长的效率比IL-2/IL-12激活的BMC高约八倍。与新鲜细胞相比,BMC和PBC的冷冻保存及随后用细胞因子刺激并未导致细胞毒性或其抑制共培养K562细胞生长能力的显著降低。然而,对于BMC,不再能检测到IL-2/IL-12组合所观察到的协同效应。这些结果表明:(1)在细胞因子培养后产生有效的自然杀伤(NK)活性方面,PBC优于BMC;(2)IL-2和IL-12的组合可能比单独使用IL-2更有效地抑制K562细胞的增殖/生长。